Journal of Biomedical Science

, Volume 14, Issue 5, pp 543–553

Modulation of liver X receptor signaling as novel therapy for prostate cancer

  • Chih-Pin Chuu
  • John M. Kokontis
  • Richard A. Hiipakka
  • Shutsung Liao
Article

DOI: 10.1007/s11373-007-9160-8

Cite this article as:
Chuu, C., Kokontis, J.M., Hiipakka, R.A. et al. J Biomed Sci (2007) 14: 543. doi:10.1007/s11373-007-9160-8

Abstract

Liver X receptors (LXRs) are important regulators of cholesterol, fatty acid, and glucose homeostasis. LXR agonists are effective for treatment of murine models of atherosclerosis, diabetes, and Alzheimer’s disease. Recently we observed that LXR agonists suppressed proliferation of prostate and breast cancer cells in vitro and treatment of mice with the LXR agonist T0901317 suppressed the growth of prostate tumor xenografts. LXR agonists appear to cause G1 cell cycle arrest in cells by reducing expression of Skp2 and inducing the accumulation of p27Kip. T0901317 induced expression of ATP-binding cassette transporter A1 (ABCA1) and delayed the progression of androgen-dependent human prostate tumor xenografts towards androgen-independency in mice. Phytosterols, the plant equivalent of mammalian cholesterol, have recently been shown to be agonists for LXRs. β-Sitosterol and campesterol, the two most common phytosterols, suppressed proliferation of prostate and breast cancer cells. The anticancer activity of phytosterols may be due to LXR signaling. This review examines the potential use of LXR signaling as a therapeutic target in prostate and other cancers.

Keywords

LXRLXR agonistprostate cancerprostate cancer progressionLNCaPT0901317phytosterolcancer therapy

Copyright information

© National Science Council Taipei 2007

Authors and Affiliations

  • Chih-Pin Chuu
    • 1
  • John M. Kokontis
    • 1
  • Richard A. Hiipakka
    • 1
  • Shutsung Liao
    • 1
  1. 1.The Ben May Department for Cancer ResearchThe University of ChicagoChicagoUSA